Sutro Biopharma (STRO) Cash from Operations (2017 - 2025)

Sutro Biopharma has reported Cash from Operations for 9 years, with the latest figure at 26435000.0 in Q4 2025.

• Quarterly Cash from Operations rose 63.15% year-over-year to 26435000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 177231000.0 (up 7.47% YoY) and the FY2025 annual result came in at 177231000.0, up 7.47% from the prior year.
• Cash from Operations climbed to 26435000.0 in Q4 2025 per STRO's latest filing, from 38189000.0 in the prior quarter.
• Over five years, Cash from Operations peaked at 65854000.0 in Q3 2022 and troughed at 71738000.0 in Q4 2024.
• A 5-year average of 27925850.0 and a median of 30812500.0 in 2021 frame the typical range for Cash from Operations.
• The sharpest annual moves came in 2022 and 2023: Cash from Operations soared 369.83% in 2022, then slumped 879.13% in 2023.
• Over 5 years, Cash from Operations stood at 21580000.0 in 2021, then declined by 10.58% to 23864000.0 in 2022, then soared by 158.97% to 14072000.0 in 2023, then plunged by 609.79% to 71738000.0 in 2024, then surged by 63.15% to 26435000.0 in 2025.
• According to Business Quant data, Cash from Operations over the past three periods registered 26435000.0, 38189000.0, and 44724000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.